OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluation of apremilast, an oral phosphodiesterase 4 inhibitor, for refractory cutaneous dermatomyositis: A phase 1b clinical trial
Risa Konishi, Ryota Tanaka, Sae Inoue, et al.
The Journal of Dermatology (2021) Vol. 49, Iss. 1, pp. 118-123
Closed Access | Times Cited: 8
Risa Konishi, Ryota Tanaka, Sae Inoue, et al.
The Journal of Dermatology (2021) Vol. 49, Iss. 1, pp. 118-123
Closed Access | Times Cited: 8
Showing 8 citing articles:
Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast
Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, et al.
Reumatismo (2025)
Open Access
Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, et al.
Reumatismo (2025)
Open Access
Apremilast for Recalcitrant Cutaneous Dermatomyositis: A Review of Current Literature
Manjit Kaur Mohi, Jessica Kaffenberger, Judith C. Lin, et al.
International Journal of Dermatology (2025)
Closed Access
Manjit Kaur Mohi, Jessica Kaffenberger, Judith C. Lin, et al.
International Journal of Dermatology (2025)
Closed Access
Current and new targets for treating myositis
Siamak MoghadamâKia, Chester V. Oddis
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102257-102257
Closed Access | Times Cited: 14
Siamak MoghadamâKia, Chester V. Oddis
Current Opinion in Pharmacology (2022) Vol. 65, pp. 102257-102257
Closed Access | Times Cited: 14
Possible future avenues for myositis therapeutics: DM, IMNM and IBM
Caoilfhionn M Connolly, Lotta Plomp, Julie J. Paik, et al.
Best Practice & Research Clinical Rheumatology (2022) Vol. 36, Iss. 2, pp. 101762-101762
Open Access | Times Cited: 10
Caoilfhionn M Connolly, Lotta Plomp, Julie J. Paik, et al.
Best Practice & Research Clinical Rheumatology (2022) Vol. 36, Iss. 2, pp. 101762-101762
Open Access | Times Cited: 10
Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature
Kareem G. Elhage, Raymond Zhao, Mio Nakamura
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 1815-1831
Open Access | Times Cited: 6
Kareem G. Elhage, Raymond Zhao, Mio Nakamura
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 1815-1831
Open Access | Times Cited: 6
Efficacy and safety of apremilast in a patient with paraneoplastic dermatomyositis with resistant skin disease
Nicola Cabas, M Turina, Stefano Pizzolitto, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 2
Nicola Cabas, M Turina, Stefano Pizzolitto, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 2
Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases
Nathaniel Goldman, Joseph Han, Avery LaChance
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2285-2312
Open Access | Times Cited: 4
Nathaniel Goldman, Joseph Han, Avery LaChance
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 2285-2312
Open Access | Times Cited: 4
Novedades en la inmunoterapia de las enfermedades del tejido conectivo autoinmunes. Parte II: esclerodermia localizada y dermatomiositis
Isabel Bielsa Marsol
Piel (2024) Vol. 40, Iss. 2, pp. 104-111
Closed Access
Isabel Bielsa Marsol
Piel (2024) Vol. 40, Iss. 2, pp. 104-111
Closed Access
